Skip to main content

Antipsychotic long-acting injections: Prescribing practice in the UK

  • Thomas R. E. Barnes (a1), Amber Shingleton-Smith (a2) and Carol Paton (a3)

Data from the USA, Australia and Europe suggest that the proportion of patients with schizophrenia prescribed an antipsychotic long-acting injection (LAI) varies from around a quarter to a third. Use of LAIs has been associated with male gender and younger age.


To characterise the use of LAIs in people with schizophrenia in three clinical settings in the UK.


The study used audit data from quality improvement programmes conducted by the Prescribing Observatory for Mental Health.


Long-acting injections were found to be prescribed for between a quarter and a third of patients, depending on the clinical setting. Flupentixol, risperidone and zuclopenthixol were most commonly prescribed and were combined with an oral antipsychotic in half of cases, frequently constituting high-dose prescribing. The use of LAIs was not consistently associated with age, gender or ethnicity.


Antipsychotic LAIs are commonly prescribed. We did not replicate previous findings with respect to demographic variables associated with their use.

Corresponding author
Carol Paton, Division of Psychological Medicine, Imperial College, Charing Cross Campus, Reynold's Building, St Dunstan's Road, London W6 8RP, UK. Email:
Hide All

Declaration of interest

Over the past 3 years T.B. has acted as consultant to Servier, Johnson & Johnson and Bristol-Myers Squibb, and C.P. has acted as a consultant to Eli Lilly.

Hide All
1 Barnes, TRE, Curson, DA. Long-acting depot antipsychotics: a risk–benefit assessment. Drug Saf 1994; 10: 464–79.
2 Adams, CE, Fenton, MKP, Quraishi, S, David, AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290–9.
3 Schooler, NR. Relapse and rehospitalisation: comparing oral and depot antipsychotics. J Clin Psychiatry 2003; 64 (suppl 16): 14–7.
4 Tiihonen, J, Wahlbeck, K, Lonnqvist, J, Klaukka, T, Ioannidis, JPA, Volavka, J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalization due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333: 224.
5 Zhu, B, Ascher-Svanum, H, Shi, LB, Faries, D, Montgomery, W, Marder, SR. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv 2008; 59: 315–17.
6 Svedberg, B, Backenroth-Ohsako, G, Lützén, K. On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medication. Int J Ment Health Nurs 2003; 12: 110–8.
7 Kane, JM, Aguglia, E, Altamura, AC, Ayuso Gutierrez, JL, Brunello, N, Fleischhacker, WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998; 8: 5566.
8 Bloch, Y, Mendlovic, S, Strupinsky, S, Altshuler, A, Fennig, S, Ratzoni, G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 2001; 62: 855–9.
9 Hay, J. Complications at site of injection of depot neuroleptics. BMJ 1995; 311: 421.
10 Jones, JC, Day, JC, Taylor, JR, Thomas, CS. Investigation of depot neuroleptic injection site reactions. Psychiatr Bull 1998; 22: 605–7.
11 Barnes, TRE. Why indeed? Invited commentary on: Why aren't depot antipsychotics prescribed more often and what can be done about it? Advan Psychiatr Treat 2005; 11: 211–3.
12 Ziguras, S, Lambert, TJR, McKenzie, DP, Pennella, J. The influence of client's ethnicity on psychotropic medication management in community mental health services. Aust N Z J Psychiatry 1999; 33: 882–8.
13 Moore, TA, Buchanan, RW, Buckley, PF, Chiles, JA, Conley, RR, Crismon, ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007; 68; 1751–62.
14 Lehman, AF, Lieberman, JA, Dixon, LB, McGlashan, TH, Miller, AL, Perkins, DO, et al. Practice guideline for the treatment of patients with schizophrenia, 2nd edition. Am J Psychiatry 2004; 161 (suppl): 156.
15 National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update). National Clinical Practice Guideline 82. NICE, 2009 (
16 Roberts, G, Dorkins, E, Wooldridge, J, Hewis, E. Detained – what's my choice? Part 1: Discussion. Advan Psychiatr Treat 2008; 14: 172–80.
17 Dencker, S, Axelsson, R. Optimising the use of depot antipsychotics. CNS Drugs 1996; 6: 367–81.
18 Covell, NH, Jackson, CT, Evans, AC, Essock, SM. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002; 28: 1729.
19 Humberstone, V, Wheeler, A, Lambert, T. An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Aust N Z J Psychiatry 2004; 38: 240–5.
20 Foster, K, Meltzer, H, Gill, B. Adults with a psychotic disorder living in the community. OPCS Surveys of Psychiatric Morbidity in Great Britain, Report 8. TSO (The Stationery Office), 1996.
21 Paton, C, Lelliott, P, Harrington, M, Okocha, C, Sensky, T, Duffett, R. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol 2003; 17: 223–9.
22 Hanssens, L, De Hert, M, Wampers, M, Reginster, JY, Peuskens, J. Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Clin Pract Epidemiol Ment Health 2006; 2: 11.
23 Jablensky, A, McGrath, J, Herrman, H, Castle, D, Gureje, O, Evans, M, et al. Psychotic disorders in urban areas: an overview of the study on low prevalence disorders. Aust N Z J Psychiatry 2000; 34: 221–36.
24 Xiang, YT, Weng, YZ, Leung, CM, Tang, WK, Ungvari, GS. Clinical and social determinants of use of depot antipsychotics for patients with schizophrenia in Hong Kong. Hong Kong J Psychiatry 2006; 16: 71–5.
25 Lehman, AF, Steinwachs, DM. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull 1998; 24: 1120.
26 West, JC, Marcus, SC, Wilk, J, Countis, LM, Regier, DA, Olfson, M. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 2008; 34: 9951001.
27 Paton, C, Barnes, TRE, Cavanagh, MR, Taylor, D, Lelliott, P, POMH–UK Project Team. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 2008; 192: 435–9.
28 Barnes, TRE, Paton, C, Cavanagh, MR, Hancock, E, Taylor, DM, UK Prescribing Observatory for Mental Health. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007; 33: 1397–401.
29 Barnes, TRE, Paton, C, Hancock, E, Cavanagh, MR, Taylor, D, Lelliott, P, et al. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr Scand 2008; 118: 2633.
30 World Health Organization. The ICD–10 Classification of Mental and Behavioural Disroders. Clinical Description and Diagnostic Guidelines. WHO, 1992.
31 Priebe, S, Fakhoury, W, Watts, J, Bebbington, P, Burns, T, Johnson, S, et al. Assertive outreach teams in London: patient characteristics and outcomes. Pan-London Assertive Outreach Study, Part 3. Br J Psychiatry 2003; 183: 148–54.
32 Anderson, J. The interface with forensic services. In Psychiatric Intensive Care (2nd edn) (eds Beer, MD, Pereira, S, Paton, C): 191201. Cambridge University Press, 2008.
33 Shi, L, Ascher-Svanum, H, Zhu, B, Faries, D, Montgomery, W, Marder, SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 2007; 58: 482–8.
34 Herriot, P, Kheirani, K. Survey of depot antipsychotic prescribing in southern Adelaide. Australas Psychiatry 2005; 13: 253–7.
35 Bains, JJS, Nielssen, OB. Combined depot antipsychotic medications with novel antipsychotics in forensic patients: a practice in search of a principle. Psychiatr Bull 2003; 27: 14–6.
36 Royal College of Psychiatrists. Consensus Statement on High-Dose Antipsychotic Medication. (Council Report CR138). Royal College of Psychiatrists, 2006.
37 Mahadun, PN, Marshall, M. Insight and treatment attitude in schizophrenia: comparison of patients on depot and atypical antipsychotics. Psychiatr Bull 2008; 32: 53–6.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Full text views

Total number of HTML views: 0
Total number of PDF views: 10 *
Loading metrics...

Abstract views

Total abstract views: 31 *
Loading metrics...

* Views captured on Cambridge Core between 3rd January 2018 - 19th March 2018. This data will be updated every 24 hours.

Antipsychotic long-acting injections: Prescribing practice in the UK

  • Thomas R. E. Barnes (a1), Amber Shingleton-Smith (a2) and Carol Paton (a3)
Submit a response


No eLetters have been published for this article.


Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *